1. Home
  2. NVGS vs TYRA Comparison

NVGS vs TYRA Comparison

Compare NVGS & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Navigator Holdings Ltd. (Marshall Islands)

NVGS

Navigator Holdings Ltd. (Marshall Islands)

HOLD

Current Price

$18.85

Market Cap

1.3B

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$36.36

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVGS
TYRA
Founded
1997
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
NVGS
TYRA
Price
$18.85
$36.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$21.50
$46.38
AVG Volume (30 Days)
521.5K
1.1M
Earning Date
03-11-2026
03-02-2026
Dividend Yield
1.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.55
$6.42
52 Week High
$21.36
$39.15

Technical Indicators

Market Signals
Indicator
NVGS
TYRA
Relative Strength Index (RSI) 45.74 56.02
Support Level $17.38 $30.10
Resistance Level $21.36 $39.15
Average True Range (ATR) 0.73 2.16
MACD -0.05 -0.18
Stochastic Oscillator 35.82 48.54

Price Performance

Historical Comparison
NVGS
TYRA

About NVGS Navigator Holdings Ltd. (Marshall Islands)

Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: